Patient Resources / Clinical Trials
ImmusanT is advancing the development of their lead product, Nexvax2®, which is a therapeutic vaccine for the treatment of celiac disease. For the Nexvax2® therapy, ImmusanT has successfully established cGMP drug manufacturing, pharmacokinetics and toxicology studies, and preclinical proof-of-concept in a transgenic mouse model. In addition, ImmusanT has completed three Phase 1 clinical trials demonstrating that Nexvax2® is well tolerated, safe, and effective in human subjects.
A further Phase 1 clinical study is currently underway in Australia and New Zealand (https://clinicaltrials.gov/ct2/show/NCT02528799). As a next step in the clinical development of Nexvax2, this study will provide data to fine-tune the dosing plan to be used in a larger, multinational Phase 2 study that is expected to commence in early 2017. More details on this Phase 2 study will be posted on clinicaltrials.gov.
Type 1 Diabetes
ImmusanT is also currently recruiting for a clinical study investigating the relationship between Celiac Disease and Type 1 Diabetes at the Joslin Diabetes Center. To learn more about this trial, please visit https://clinicaltrials.gov/ct2/show/NCT01932476.
If you are interested in learning more about ImmusanT-sponsored clinical trials, please visit our Learn More page.